Found: 6
Select item for more details and to access through your institution.
ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection.
- Published in:
- Parasitology Research, 2021, v. 120, n. 12, p. 4037, doi. 10.1007/s00436-021-07342-1
- By:
- Publication type:
- Article
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.
- Published in:
- Vaccines, 2020, v. 8, n. 2, p. 289, doi. 10.3390/vaccines8020289
- By:
- Publication type:
- Article
Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
- Published in:
- Parasite Immunology, 2020, v. 42, n. 12, p. 1, doi. 10.1111/pim.12784
- By:
- Publication type:
- Article
Development of an Affordable ELISA Targeting the SARS-CoV-2 Nucleocapsid and Its Application to Samples from the Ongoing COVID-19 Epidemic in Ghana.
- Published in:
- Molecular Diagnosis & Therapy, 2023, v. 27, n. 5, p. 583, doi. 10.1007/s40291-023-00655-0
- By:
- Publication type:
- Article
Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
- Published in:
- Medical Microbiology & Immunology, 2021, v. 210, n. 2/3, p. 133, doi. 10.1007/s00430-021-00707-4
- By:
- Publication type:
- Article
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.
- Published in:
- NPJ Vaccines, 2020, v. 5, n. 1, p. 1, doi. 10.1038/s41541-020-00224-0
- By:
- Publication type:
- Article